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Abstract
Background: C-X-C Motif Chemokine Receptor (CXCR4) is an oncogene that widely studied and associated with worse
clinicopathological features and prognosis outcome on many types of cancer. Beside that, signiﬁcance of CXCR4
expression on clinicopathological features and prognostic on osteosarcoma (OS) require further validation.
Aim: We conducted a meta-analysis to evaluate association between positive CXCR4 expression with clinicopathological features, and prognosis in OS.
Methods: Literature searches on Pubmed, Cochrane Library and Web of Science was conducted systematically up to
December 2021 to ﬁnd relevant references. Effect of CXCR4 expression on clinicopathological characteristic and prognostic were analyzed using Review Manager 5.4 (Cochrane Collaboration, Oxford, UK). Signiﬁcance value less than 0.05
was considered statistically signiﬁcant.
Results: By considering inclusion and exclusion criteria, 940 patients from 12 studies were suitable to included in
qualitative analysis, and 10 studies were suitable for quantitative analysis. Association between CXCR4 expression and
OS clinicopathological features was found signiﬁcant on metastasis (OR ¼ 4.01, 95%CI ¼ 1.58e10.18; p ¼ 0.003), stage
(stage III & IV vs I & II, OR ¼ 6.52, 95%CI ¼ 1.05e40.62; p ¼ 0.04), and tumor primary site (femur/tibia vs other,
OR ¼ 1.60, 95%CI ¼ 1.04e2.45; p ¼ 0.03), but not associated with histological type, gender, and age. Furthermore, CXCR4
expression is associated with poor overall survival in OS (HR ¼ 2.13, 95%CI ¼ 1.78e2.55; p < 0.001).
Conclusion: In conclusion, the results of our meta-analysis suggest that CXCR4 expression may be valuable as a histopathological predictor of poor clinicopathological features and prognosis of OS.
Keywords: Clinicopathology, CXCR4, Meta-analysis, Osteosarcoma, Prognosis

1. Background

O

steosarcoma (OS) is the most common primary malignant bone tumor which is characterized by its rapid growth, strong invasiveness, and
high rate of metastasis to the lungs, with a huge
worldwide incidence [1]. It has a predilection for
affecting children and adolescents between the ages
of 10 and 19, predominantly occurs among males [2].
About 10e20% of osteosarcoma patients present
with metastasis at early diagnosis, with the most
common locations being the lung (85%), bone
(8e10%), and lymph nodes. The presence of metastasis in patients with osteosarcoma develops poor

prognosis and decreases survival rate outcomes [3,4].
Five-year overall survival for osteosarcoma patients
is around 70% compared to patients with metastatic
disease who show only 10%e30%. The current
comprehensive treatment consisting of neoadjuvant
chemotherapy and surgical resection has improved
the ﬁve-year survival rate [5]. However, the prognosis in osteosarcoma with metastatic disease remains poor due to changes in chemotherapy
regimen type, local recurrence, and type of metastasis leading to ineffective treatment [6,7]. Furthermore, 60% of osteosarcoma patients have not shown
signiﬁcant lung metastasis at initial diagnosis even
though micrometastases exist [3,4]. Therefore, it is
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important to determine valuable prognostic markers
for early detection of tumor metastasis and better
understanding of clinicopathological changes that
could improve the overall prognosis and survival of
osteosarcoma patients signiﬁcantly.
The C-X-C Motif Chemokine Receptor (CXCR4) is
known as the most widely expressed chemokine
receptor and is involved in numerous physiological
and pathological conditions in the human body. It
binds to its ligand named stromal derived factor-1
(SDF-1) that is expressed by most cells, including
hematopoietic and endothelial cells in the lung,
liver, skeletal muscle, and brain [8]. Colorectal,
breast, kidney, lung, liver, and gallbladder cancers
have all been associated with a poor prognosis when
CXCR4 overexpression is present [9]. CXCR4 also
contributes to angiogenesis, metastasis, tumor
growth and invasion, even relapse and therapeutic
resistance in some cancers [10]. Previous studies
have shown a correlation of CXCR4 expression with
prognosis in patients with bone and soft tissue sarcoma, but the uncertainty remains [11e21]. However, the prognostic role of CXCR4 expression in
patients with osteosarcoma and its correlation with
the clinicopathological features have not been
analyzed speciﬁcally. Therefore, we performed this
meta-analysis to identify studies from published
literature and to evaluate whether expression of
CXCR4 in patients with osteosarcoma can be a
suitable prognostic and histopathological marker in
the correlation to overall survival and clinicopathological features.

writers independently assessed the yielded literatures (GYAY and JN). Any disagreement on the
eligibility of selected literatures were discussed to
meet consensus. Study selection process is presented using the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
ﬂow chart [11]. The Newcastle Ottawa Scale (NOS)
was used to assess the quality of the literature
because all of the included studies were nonrandomized clinical trials. The NOS score 7e9 was
considered high quality and was included in this
review.

2. Method

2.2. Statistical analysis

We conducted searches in biomedical literature
databases such as PubMed, Web of Science, and
Cochrane Library. Implemented keywords were as
follows: “Chemokine receptor type 4”, “C-X-C chemokine receptor type 4”, “CXCR4”, “osteosarcoma”,
and “bone sarcoma”. The Boolean operators “AND”
and “OR” are used to combine the keywords. The
results were later ﬁltered by considering inclusion
criteria including: (1) written in English; (2) human
research that included osteosarcoma patients that
was conﬁrmed by pathological or histological
assessment; and (3) focused on exploration of correlation between CXCR4 positive expression with
osteosarcoma prognostic and clinicopathological
features. Studies were excluded if they met any of
the following criteria: (1) non-English literature; (2)
patents, cases, reviews, letters, and conference abstracts; and (3) non-human research. Then, two

The role of positive or high CXCR4 expression on
prognosis was calculated by pooled hazard ratio
(HR), and on clinicopathological features (including
metastasis, gender, age, tumor stage, histological
type, and tumor site) were calculated by pooled odd
ratio (OR). Hazard ratio data is used either from
readily available data from literatures or extracted
from another form of time-to-event data outcome
with methods introduced by Tierney et al., both data
are measured with a 95% conﬁdence interval (95%
CI) [12]. The meta-analysis model that used were
determined by the analysis heterogeneity score (I2
statistic). The random effect model applied if I2
>50%; otherwise, ﬁxed effect model is used. Publication bias was calculated by Begg's funnel plot,
indicated by its symmetry between logHRs or logORs, and its corresponding standard errors (SEs).
Result with a signiﬁcance value less than 0.05

2.1. Data extraction
Demanded data were extracted, which include: (1)
basic literature information (ﬁrst author's last name,
year of publication, type of study, state/location of
sample source, duration of follow-up, study period,
and study design); (2) Patient sociodemographics,
including race, mean age, gender, and CXCR4
expression status; (3) expression assessment
method, which includes the assessment instrument,
the source of the assessment instrument, the deﬁnition of positive expression/cut-off value, the
expression site (nucleus, membrane, or cytoplasm),
and the antibody type and dilution level if an
immunohistochemistry (IHC) instrument is used; (4)
clinicopathological outcome, including metastasis,
tumor stage, primary tumor site, and histological
type; (5) prognosis outcome, including overall survival data.

ORIGINAL ARTICLE

BioMedicine
2022;12(4):34e43

36

G.N. ANANDA WIRA KUSUMA ET AL
CXCR4 EXPRESSION EFFECTS IN OSTEOSARCOMA

BioMedicine
2022;12(4):34e43

ORIGINAL ARTICLE
Fig. 1. PRISMA Flow chart as visualization of study selection process.

( p < 0.05) was accounted as a statistically signiﬁcant
result. All statistical data analyses were conducted
using Review Manager 5.4 (Cochrane Collaboration,
Oxford, UK).

3. Result
3.1. Selected studies characteristics
Flow chart represents the selection process
described in Fig. 1. Through the selection process,

12 studies were suitable to be included in qualitative
analysis, and 10 studies were suitable to be included
in quantitative analysis. General characteristics of 12
selected studies were extracted including study
design, number of patients, sample source, age, and
time to follow up duration, as shown in Table 1. In
total, 940 OS patients were included as samples,
mostly from Asian races (8/12 studies). NOS score
for each study ranged from 7 to 9, an ideal score as
mentioned in the method section.
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Table 1. General characteristics of each study selected for the meta-analysis.
No.

Study

Study design

Sample source

Number
of patients

Age

Time of follow
up (months)

NOS
Score

1
2
3
4
5
6
7
8
9
10
11
12

Gong, 2020 [13]
Mardani, 2019 [14]
Pollino, 2019 [15]
Ren, 2015 [16]
Lu, 2015 [17]
Guan, 2015 [18]
Guo, 2014 [19]
Ma, 2011 [20]
Baumhoer, 2011 [21]
Lin, 2010 [22]
Oda, 2006 [23]
Laverdiere, 2005 [24]

Prospective
Prospective
Prospective
Retrospective
Retrospective
Prospective
Retrospective
Retrospective
Retrospective
Retrospective
Retrospective
Retrospective

China
Iran
Italy
China
China
China
China
China
Germany
China
Japan
USA

73
50
48
96
96
107
98
63
145
56
30
47

NA
19 ± 8.9
19
NA
18 (8e49)
16.5 (8e48)
NA
16 (8e48)
22.9 (4e88)
22.4 (7e67)
15 (7e69)
16 (4e77)

36
NA
48
57.5 (6e171)
Minimum 36
34 (5e65)
NA
66 (12e120)
NA
33.5 (20e75)
38.5 (9e145)
41 (1e329)

9
7
9
8
9
8
7
8
8
7
8
7

NA: Not Applicable.

In detail, quantitative measurement of CXCR4
methods of each study were also extracted. Immunohistochemistry (IHC) was mostly utilized in our
selected eligible studies as a CXCR4 expression indicator, although the types, dilutions, and sources varied. Five studies also conducted reverse transcription
polymerase chain reaction (RT-PCR) as a measurement instrument for CXCR4 expression. CXCR4 distribution assessed in each study ranged from nucleus,
cytoplasm, and membrane, or a combination of those.
Additionally, the deﬁnition of expression varied from
each study; the immunostaining score, which ranged
from 2-4, was frequently chosen as the cutoff number.
Detailed characteristics of the included studies are
shown in Table 2.

3.2. Association between CXCR4 expression and
osteosarcoma clinicopathological features
Positive CXCR4 expression in OS and its correlation with metastasis was assessed in 10 studies with
signiﬁcant heterogeneity (I2 ¼ 85%, p < 0.001).
Pooled OR calculated under a random-effect model
yielded 4.01 (95%CI ¼ 1.58e10.18; p ¼ 0.003), showed
a signiﬁcantly higher expression of CXCR4 in metastatic OS than in nonmetastatic OS.
CXCR4 expression in OS was not signiﬁcantly
associated with either male or female (OR ¼ 0.83;
95%CI ¼ 0.57e1.21; p ¼ 0.33) and also unrelated to
age (OR ¼ 1.07; 95%CI ¼ 0.71e1.62; p ¼ 0.75).
CXCR4 expression in OS was signiﬁcantly associated with both features, which yielded pooled OR

Table 2. Detailed characteristic of each study selected for the meta-analysis.
No Study

Method(s) Antibody Source for IHC

Antibody
type

Antibody Deﬁnition of
dilution
CXCR4 expression

CXCR4 cellular
distribution

1
2

Gong,2020
Mardani, 2019

IHC
IHC

Santa cruz Biotechnology
Medaysis RM0407RTU7

Polyclonal
1:100
Monoclonal NA

Total IHC score 4
Total IHC Score 3

3

Pollino,2019

Total IHC Score 3

Ren,2015
Lu,2015

Polyclonal
Polyclonal

Total IHC score 4
Total IHC score 4

6

Guan,2015

Monoclonal 1:75

Total IHC score 5

NA

7

Guo,2014

Monoclonal 1:200

Total IHC Score 2

8

Ma, 2011

qRT-PCR,
IHC
IHC

Thermo Fisher Scientiﬁc,
Abcam ab2074.
Abcam ab2074
Invitrogen Life Technologies,
Abcam ab2074
Roche Molecular
Biochemicals,
R&D System
ab58176,
Abcam
Santa Cruz Biotechnology

Monoclonal 1:1000

4
5

RT-PCR,
IHC
IHC
qRT-PCR
IHC
qRT-PCR,
IHC

Cytoplasm
Cytoplasm and
membrane
Cytoplasm and
nucleus
Cytoplasm
Cytoplasm

Monoclonal 1:100

9

Baumhoer, 2011

IHC

Ventana BenchMark XT

Polyclonal

1:500

10

Lin,2010

IHC

Boster Biological Technology, Polyclonal

1:400

11

Oda,2006

IHC

BD Pharmingen clone 125G

Monoclonal 1:100

12

Laverdiere, 2005 qRT-PCR

NA

NA

1:100
NA

NA

IHC: Immunohistochemistry; RT-PCR: reverse transcription polymerase chain reaction.

Cytoplasm and
membrane
NA
Nucleus, cytoplasm
and membrane
Total IHC Score 3 Cytoplasmic and
membrane
Nuclear or
Cytoplasm and
cytoplasmic staining nucleus
Positive cells >1%
Total IHC score 2 Cytoplasm and
nucleus
NA
NA
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6.52 (95%CI ¼ 1.05e40.62; p ¼ 0.04), under randomeffect model, and 1.60 (95%Cl ¼ 1.04e2.45,
p ¼ 0.03), under ﬁxed-effect model, respectively.
This means positive CXCR4 expression on OS was
associated with higher tumor stages (III and IV),

BioMedicine
2022;12(4):34e43

and more likely to appear in femur or tibia as its
primary site.
Considering histological type, CXCR4 expression
in OS was not signiﬁcantly associated with either
osteoblastic or chondroblastic type, which yielded

Fig. 2. Forest plots show the association between CXCR4 positive expression and the following clinicopathological characteristics of OS: (A)
metastasis, (B) gender, (C) stage, (D) and tumor site.
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Fig. 2. (Continued).

OR 0.73 (95%CI ¼ 0.40e1.33, p ¼ 0.30). Each analysis
result was provided as a forest plot shown in Fig. 2.

p < 0.001), meaning patients with high CXCR4
expression had a worse prognosis. The forest plot
for survival analysis is shown in Fig. 3.

3.3. Association between CXCR4 expression and
osteosarcoma prognosis

3.4. Sensitivity and publication bias

CXCR4 expression and its effect on osteosarcoma
patient's overall survival was assessed in 8 studies
that yielded a pooled HR 2.13 (95%Cl ¼ 1.78e2.55,

Sensitivity test was done by removing studies
one by one and assessing OR, HR, and 95%Cl
value stability. The results are as follows:
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Fig. 3. Forest plot represents the overall survival of patients with positive CXCR4 expression on OS.

considering clinicopathology features, each feature
had an OR ranged from 2.94 to 5.31 for metastasis,
0.7e0.94 for gender, 1.24e1.85 for tumor primary
site, 0.61e0.86 for histological type, 0.99e1.13 for
age, and HR ranged from 1.97 to 2.19 for overall
survival. These ﬁndings showed consistent and
stable results. The funnel plot of meta-analysis
shows large symmetry, which suggests that no
publication bias exists in the meta-analysis, as
shown in Fig. 4.

4. Discussion
Osteosarcoma, the dominant primary bone malignancy that has high morbidity, and mortality rate,
and may be acquired by all age groups, mostly in
children and young adults [25]. Due to the high
incidence in children and young adults, prolonging
life expectancy by precision therapy is a necessary
goal in the treatment of OS. Emerging evidence of
prognostic factors contributes to early prevention of
worsening conditions, complications, and decreased
mortality risk. Gene-based prognostic factors also
allow precise screening and suggest potential therapeutic targets for future personalized medicine,
thus helping clinicians specify treatment options
[26]. Recently, several speciﬁc biomarkers to determine prognostic factors have been found to formulate future therapy for OS [27].
Previous meta-analysis conducted by Li et al. [28],
assessed the correlation of clinicopathological and
prognostic signiﬁcance of CXCR4 expression with
soft tissue and bone sarcoma. The results were signiﬁcant for tumor metastasis and stages. However,
as the analysis merged patient's criteria between
different types of sarcomas, the results were unspeciﬁed for OS.
Current meta-analysis combined studies that
assessed the association of CXCR4 expression with

prognosis and clinicopathology characteristics speciﬁcally in OS patients. Along with previous reports,
high expression of CXCR4 within the metastatic and
advanced stage OS patients was also found. The
possible mechanism behind this process is that
CXCR4 plays a signiﬁcant role in regulating the
microtubule spindle. CXCR4 also held as an integral
part of mitosis regulator and has an inhibitory effect
on apoptosis [29,30]. CXCR4 expression in osteosarcoma cells showed that it enhances the proliferation of MG-63 cell lines and migration and inhibits
apoptosis [27]. A recent study reported that the
LM8cell line found in mice with osteosarcoma
expressed a high CXCR4 level. CXCR4 holds a
major role in regulating the survival, migration, and
apoptosis of LM8 cells [30]. The latest study reported that Mesenchymal Stem Cells (MSCs) within
the tumor stroma and Vascular Endothelial Growth
Factor (EFGR) advance the metastasis process [31].
The involvement of VEGF facilitates the metastasis
of OS derived from MSCs, otherwise CXCR4 regulates the expression of VEGF of MSCs. Some studies
reported that CXCR4 might modulate tumor cells to
metastasize to a speciﬁc organ as it controls angiogenesis [32e35]. Some studies also found that the
ability of CXCR4 to regulate neovasculature is
accountable for addressing tumor cell metastasis,
especially in solid organs [23,24,36].
The CXCR4 expression in OS based on gender
separation showed no signiﬁcant association for
both male and female patients, the same result
applied for age. Those ﬁndings were conﬁrmatory,
since they aligned with previous studies [23,27].
Inversely, CXCR4 expression signiﬁcantly correlates
with the tumor primary site. This ﬁnding is misaligned with previous studies may be due to the
involvement of updated studies included in the
analysis. When compared by its histological type,
the meta-analysis shows no signiﬁcant correlation
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Fig. 4. Begg's funnel plot representing publication bias of each meta-analysis: (A) metastasis, (B) gender, (C) stage, (d) tumor site (e) histological type,
(f) age and (g) hazard ratio. *SE(log[OR]) = Standard error multiplied log scale of odd ratio; SE(log[HR]) = Standard error multiplied log scale of
hazard ratio.
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either with the osteoclastic nor chondroblastic type.
Currently, our meta-analysis shows up to be the ﬁrst
analysis that assesses the correlation of CXCR4
expression with OS histological type.
The majority of previous studies showed a
diminished level of survival possibility which
aligned with our result. The group with CXCR4
expression also showed a depleted survival rate in
other bony malignancies [37]. This poor prognosis
may correlate with the metastatic process, and
tumor stage that signiﬁcantly higher CXCR4
expression [27]. Furthermore, the ﬁndings of those
CXCR4 expression primary site in OS patients
might help physicians to determine the strategy
toward the disease. Physicians should be more
aware of the worsening clinicopathological features
and prognosis in such cases. Further exploration of
therapy focusing on CXCR4 may also be developed.
Regarding publication bias, we performed Begg's
funnel plot test in order to assess any publication
bias. The funnel plot of the meta-analysis shows
large symmetry which suggests that no publication
bias exists in the meta-analysis. Sensitivity tests
were also performed, which yielded consistent and
stable results. Several limitations of this study
should also be noted that this study's inclusion
criteria were limited to only English literature and
may be biased by inaccessible data in some
excluded studies. Another limitation of this study
was determining the HR, as some papers may not
provide it directly. By then, we need to calculate
directly from the KaplaneMeier curves in the papers. Further studies should be conducted in order
to conﬁrm this interpretation.
To conclude, this study demonstrated CXCR4 is
signiﬁcantly related to metastasis, tumor stage,
tumor primary site, and overall survival in OS.
Possible advantages provided by this study might
be to consider CXCR4 expression as either a prognostic factor or novel therapeutic target. Furthermore, to conﬁrm our ﬁndings, additional welldesigned research is necessary.
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